Seiwert, Tanguy Y.
Wildsmith, Sophie http://orcid.org/0000-0003-2090-5491
Fayette, Jérôme
Harrington, Kevin
Gillison, Maura
Ahn, Myung-Ju
Takahashi, Shunji
Weiss, Jared
Machiels, Jean-Pascal
Baxi, Shrujal
Baker, Valerie
Evans, Brent
Morsli, Nassim
Jill Walker,
Real, Katia
L’Hernault, Anne
Psyrri, Amanda
Clinical trials referenced in this document:
Documents that mention this clinical trial
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
https://doi.org/10.1007/s00262-024-03643-3
Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Funding for this research was provided by:
AstraZeneca
Article History
Received: 14 December 2023
Accepted: 26 January 2024
First Online: 2 March 2024
Declarations
:
: TYS has received funding (to institution) from AstraZeneca, Bristol Myers Squibb, Cue Biopharma, Kura, Merck, Nanobiotix, Regeneron, and Roche; and honoraria as an advisor from Bayer, Cue Biopharma, Innate Pharma, IO Biotech, Merck, Nanobiotix, NEKTAR, Sanofi, and VIR. SW and NM are employees of and shareholders in AstraZeneca; and report published patent WO2021228988A1. JF has served in a consulting or advisory role for Bristol Myers Squibb, Innate Pharma, Merck, MSD, Rakuten, and Roche; and has received non-financial support from Bristol Myers Squibb and MSD. KH has received research funding from AstraZeneca, Boehringer Ingelheim, MSD, and Replimune, and received consultant/advisory/honoraria fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Codiak, Inzen, Merck Serono, Mersana Therapeutics, MSD, Pfizer, and Replimune. MG has received research funding from Agenus, Bristol Myers Squibb, Cullinan, Genentech, Genocea, Kura Oncology, LaRoche, NRG, and the University of Cincinnati; has served in a consulting or advisory role for Amgen, Aspyrian, AstraZeneca, Bayer, Bicara, BioMimetix, BioNTech AG, Bristol Myers Squibb, Celgene, Coherus, Debiopharm, Eisai, EMD Serono, Genocea, Gilead, Istari Oncology, iTeos, Ipsen, Kura Oncology, LLX Solutions, Merck, Mirati, Nektar, NewLink Genetics, NRG, OncLive Intellisphere, Roche, Roche Diagnostics GmbH, Seagen, Sensei, SQZ Biotech, Shattuck Labs, and TRM Oncology; has received honoraria from OncLive and Roche; and reports stock options in Sensei. M-JA has received honoraria from AstraZeneca, Bristol Myers Squibb, MSD, ONO, and Roche; and has served in a consultant or advisory role for Alpha, AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Roche, and Takeda. ST has received grants from AstraZeneca during the conduct of the study; and grants and personal fees from Bayer, Chugai, Daiichi-Sankyo, Eisai, MSD, Novartis, and Taiho outside the submitted work. JWe has stock and other ownership interests in Achilles, Enfuego, Lyell, Nektar, Nuvalent, and Vesselon; has served in a consultant or advisory role for AbbVie, AstraZeneca, Azitra, BeiGene, Blueprint Medicines, Boehringer Ingelheim, EMD Serono, G1 Therapeutics, Genentech, Genmab, Jazz, Jounce, Lilly, Nanobiotix, Pfizer, Regeneron, Saatchi Wellness, and SDP Oncology; received research funding from Boehringer Ingelheim, Mirati, PDS Biotechnology, and Sumitomo Dainippon; received research funding (to institution) from Amgen, G1 Therapeutics, Immunicum, Inspirna, and Loxo/Lilly; and had travel, accommodations, or expenses paid by Mirati. J-PM has served as an advisory board member or speaker with honoraria (managed by institution) for ALX Oncology, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Cue, eTheRNA, Incyte, Innate, iTeos, Janssen, Merck Serono, NEKTAR, Novartis, Pfizer, and Roche; has received travel expenses from Amgen, Bristol Myers Squibb, MSD, and Pfizer; has served on a data safety monitoring board with honoraria for PsiOxus; has received funding (to institution) for research support from all aforementioned companies; and has received non-financial support from MSD. SB owns stock in Roche Holding AG and is an employee of Verana Health. VB is a freelance contractor for and shareholder in AstraZeneca. BE, JWa, KR, and AL are employees of and shareholders in AstraZeneca. AP has received research funding from Bristol Myers Squibb, DEMO, Kura Oncology, and Roche and received consultant/advisory/honoraria fees from AstraZeneca, Bristol Myers Squibb, HPVtRNA, Merck Serono, MSD, Nanobiotix, and Pfizer.
: The KESTREL study was conducted in accordance with the Declaration of Helsinki and was consistent with International Conference on Harmonization and Good Clinical Practice guidelines, applicable regulatory requirements, and the AstraZeneca policy on Bioethics and Human Biological Samples. The final study protocol was reviewed and approved by an ethics committee or institutional review board. Written informed consent was obtained from participants before performing any protocol-related procedures.
: Written informed consent was obtained from participants before performing any protocol-related procedures.
: Not applicable.